ASCO 2021: IMpassion130 analysis identifies tumor immune phenotypes and molecular subtypes most likely to respond to atezolizumab June 15, 2021
Metastatic pattern & tumor subtype predict survival in stage IV male breast cancer at initial diagnosis March 18, 2021